LEADS BIOLABS-B (09887) Shares Rise Over 5% as Levanxil® Clinical and Translational Data Updates for Extrapulmonary Neuroendocrine Carcinoma and Other Indications Are Presented at ESMO

Stock News10-27

LEADS BIOLABS-B (09887) shares rose more than 5%, up 4.06% as of press time to HK$36.36, with a turnover of HK$9.5152 million.

On the news front, on October 26, LEADS BIOLABS-B announced that updated clinical and translational data from four studies of Levanxil® (opaprisumimab, a PD-L1/4-1BB bispecific antibody) were presented at the 2026 European Society for Medical Oncology Annual Meeting (2026 ESMO). The presentations included a late-breaking abstract (LBA) oral presentation on the latest data for Levanxil® monotherapy in third-line or later extrapulmonary neuroendocrine carcinoma (EP-NEC); a preferred oral presentation on Levanxil® combined with chemotherapy as first-line treatment for EP-NEC; a poster presentation on Levanxil® combined with chemotherapy as first-line treatment for biliary tract cancer (BTC); and a translational research poster presentation on Levanxil® in the treatment of microsatellite stable (MSS) colorectal cancer (CRC).

Levanxil® is a bispecific antibody that simultaneously targets PD-L1 and 4-1BB, with the potential to become a pan-tumor IO 2.0 backbone therapy with survival benefits. Currently, Levanxil® has launched clinical studies across 14 indications, including 1 single-arm pivotal registrational clinical study, 1 confirmatory Phase III clinical study, and 9 proof-of-concept studies, covering multiple major cancer types and "cold tumors."

Among the 7 cancer types with existing clinical data support, Levanxil® has demonstrated outstanding clinical value and broad therapeutic prospects, including extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment